Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat

Drug Metabolism and Disposition

Volumn 42, Issue 9, 2014, Pages 1567-1574

  Ferslew, Brian C ^a,c   Köck, Kathleen ^a,d   Bridges, Arlene S ^b   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c THERAVANCE INC   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABCC4 PROTEIN, HUMAN; ENALAPRIL; ENALAPRILAT; MULTIDRUG RESISTANCE PROTEIN;

CELL LINE; HEK293 CELL LINE; HUMAN; LIVER; LIVER CELL; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; ENALAPRIL; ENALAPRILAT; HEK293 CELLS; HEPATOCYTES; HUMANS; LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84906860109     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.057554     Document Type: Article

References (43)

1. Enalaprilat for Injection Package Insert Hospira, Inc., Lake Forest, IL 60045 USA, Revised: March 2010.
2. Abe K, Bridges AS, and Brouwer KLR (2009) Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos 37:447-452.
3. Chai J, He Y, Cai SY, Jiang Z, Wang H, Li Q, Chen L, Peng Z, He X, and Wu X, et al. (2012) Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology 55:1485-1494.
4. Chang C, Pang KS, Swaan PW, and Ekins S (2005) Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 314:533-541. (Pubitemid 41043833)
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
6. de Lannoy IA, Barker F, 3rd, and Pang KS (1993) Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. J Pharmacokinet Biopharm 21:395-422.
7. de Lannoy IA and Pang KS (1986) Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. Drug Metab Dispos 14:513-520.
8. El-Sheikh AA, Greupink R, Wortelboer HM, van den Heuvel JJ, Schreurs M, Koenderink JB, Masereeuw R, and Russel FG (2013) Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. Transl Res 162:398-409.
9. Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, and Cherrington NJ (2009) Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 613:119-127.
10. Fukuda Y, Takenaka K, Sparreboom A, Cheepala SB, Wu CP, Ekins S, Ambudkar SV, and Schuetz JD (2013) Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol 84:361-371.
11. Ghibellini G, Leslie EM, Pollack GM, and Brouwer KLR (2008) Use of Tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 25:1851-1860.
12. Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, and Bachmakov I, et al. (2008) Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 8:42-52.
13. Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, Ozawa S, and Ogata H (2012) Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 27:301-306.
14. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, and Cherrington NJ (2011) Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:2395-2402.
15. Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y (2007) Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol 18:37-45. (Pubitemid 46053420)
16. Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96.
17. Köck K and Brouwer KLR (2012) A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther 92:599-612.
18. Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, and Brouwer KLR (2013) Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 42:665-674.
19. König J, Müller F, and Fromm MF (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944-966.
20. Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, and Cherrington NJ (2011) Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:1954-1960.
21. Lee JK and Brouwer KR (2010) Determination of Intracellular Volume of Rat and Human Sandwich-Cultured Hepatocytes (Abstract ID 1595). The Toxicologist. Supplement to Toxicological Sciences 114:339.
22. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, and Pang KS (2006) Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther 318:395-402.
23. Matsunaga N, Wada S, Nakanishi T, Ikenaga M, Ogawa M, and Tamai I (2014) Mathematical modeling of the in vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes. Mol Pharm 11:568-579.
24. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, 2nd, Afshari CA, and Hamadeh HK (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci 136:216-241.
25. Noel G, Le Vee M, Moreau A, Stieger B, Parmentier Y, and Fardel O (2013) Functional expression and regulation of drug transporters in monolayer- and sandwich-cultured mouse hepatocytes. Eur J Pharm Sci 49:39-50.
26. Pang KS, Cherry WF, Terrell JA, and Ulm EH (1984) Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab Dispos 12:309-313. (Pubitemid 15120549)
27. Pang KS, Wang PJ, Chung AY, and Wolkoff AW (1998) The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 28:1341-1346. (Pubitemid 28493846)
28. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, and Payne LG, et al. (1980) A new class of angiotensin-converting enzyme inhibitors. Nature 288:280-283. (Pubitemid 11165879)
29. Pfeifer ND, Bridges AS, Ferslew BC, Hardwick RN, and Brouwer KLR (2013a) Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J Pharmacol Exp Ther 347:737-745.
30. Pfeifer ND, Hardwick RN, and Brouwer KLR (2014) Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol 54:509-535.
31. Pfeifer ND, Yang K, and Brouwer KLR (2013b) Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther 347:727-736.
32. Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, Vilardell J, Roman A, Martorell J, and Capdevila L (2001) Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 23:35-38. (Pubitemid 32105962)
33. Schwab AJ, Barker F, 3rd, Goresky CA, and Pang KS (1990) Transfer of enalaprilat across rat liver cell membranes is barrier limited. Am J Physiol 258:G461-G475. (Pubitemid 20116458)
34. Swift B, Pfeifer ND, and Brouwer KLR (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446-471.
35. Tchaparian EH, Houghton JS, Uyeda C, Grillo MP, and Jin L (2011) Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos 39:2387-2394.
36. Tian L, Liu H, Xie S, Jiang J, Han L, Huang Y, and Li Y (2011) Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther 33:655-663.
37. Tocco DJ, deLuna FA, Duncan AE, Vassil TC, and Ulm EH (1982) The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos 10:15-19. (Pubitemid 12177380)
38. Tsujimoto M, Hatozaki D, Shima D, Yokota H, Furukubo T, Izumi S, Yamakawa T, Minegaki T, and Nishiguchi K (2012) Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin. Ther Apher Dial 16:580-587.
39. Ulm EH (1983) Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab Rev 14:99-110.
40. Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, and Schelling JL (1982) Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol 14:357-362. (Pubitemid 13139132)
41. Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, and Hochman JH, et al. (2005) Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35:737-753. (Pubitemid 41441523)
42. Yeung CK, Shen DD, Thummel KE, and Himmelfarb J (2014) Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 85:522-528.
43. Zamek-Gliszczynski MJ, Chu X, Polli JW, Paine MF, and Galetin A (2014) Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metab Dispos 42:650-664.